- Home
- HIMX vs ARQT Comparison
HIMX vs ARQT Comparison
Compare HIMX & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIMX
- ARQT
- Stock Information
- Founded
- HIMX 2001
- ARQT 2016
- Country
- HIMX Taiwan
- ARQT United States
- Employees
- HIMX N/A
- ARQT N/A
- Industry
- HIMX Semiconductors
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- HIMX Technology
- ARQT Health Care
- Exchange
- HIMX Nasdaq
- ARQT Nasdaq
- Market Cap
- HIMX N/A
- ARQT 1.1B
- IPO Year
- HIMX 2006
- ARQT 2020
- Fundamental
- Price
- HIMX $8.85
- ARQT $12.68
- Analyst Decision
- HIMX Buy
- ARQT Strong Buy
- Analyst Count
- HIMX 1
- ARQT 5
- Target Price
- HIMX $15.00
- ARQT $17.00
- AVG Volume (30 Days)
- HIMX 1.9M
- ARQT 2.1M
- Earning Date
- HIMX 02-13-2025
- ARQT 02-25-2025
- Dividend Yield
- HIMX 3.28%
- ARQT N/A
- EPS Growth
- HIMX 10.98
- ARQT N/A
- EPS
- HIMX 0.44
- ARQT N/A
- Revenue
- HIMX $897,257,000.00
- ARQT $138,708,000.00
- Revenue This Year
- HIMX $12.75
- ARQT $209.03
- Revenue Next Year
- HIMX N/A
- ARQT $49.00
- P/E Ratio
- HIMX $20.11
- ARQT N/A
- Revenue Growth
- HIMX N/A
- ARQT 182.84
- 52 Week Low
- HIMX $4.80
- ARQT $3.11
- 52 Week High
- HIMX $9.80
- ARQT $16.20
- Technical
- Relative Strength Index (RSI)
- HIMX 63.94
- ARQT 43.06
- Support Level
- HIMX $7.09
- ARQT $13.10
- Resistance Level
- HIMX $8.62
- ARQT $14.36
- Average True Range (ATR)
- HIMX 0.49
- ARQT 0.99
- MACD
- HIMX 0.01
- ARQT -0.32
- Stochastic Oscillator
- HIMX 86.70
- ARQT 1.95
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.